Logo

Tepnel to Acquire Orchid Diagnostics for $4.3M

Oct 31, 2003

NEW YORK, Oct. 31 (GenomeWeb News) - Orchid BioSciences and Tepnel Life Sciences announced today that Tepnel will buy Orchid's diagnostics unit for $4.3 million.

 

Under the terms of the acquisition, which is expected to close during the fourth quarter of 2003, the Manchester, UK-based instrumentation and services company will acquire the product and services business of Orchid Diagnostics in the US, UK and Belgium. The company will also assume certain liabilities of the business, and will assume control of Orchid's facilities in Stamford, Conn. and Brussels, Belgium. The companies said they expect all of Orchid Diagnostics' current employees to stay on with Tepnel.

 

"This divesture is part of Orchid's ongoing strategy to focus on those DNA testing businesses where we have a market leadership position and strong competitive advantage," Paul Kelly, CEO of Orchid BioSciences, said today in a statement.

 

The completion of the acquisition is subject to a secondary public offering of shares from Tepnel and final approval by Tepnel's shareholders.

 

Breaking News
The Scan

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.

Sequencing Study Leads to Vaccine Target in Bacteria Behind Neonatal Meningitis

Researchers eBioMedicine track down potential vaccine targets with transposon sequencing on mutant bacteria causing neonatal meningitis in mouse models of the disease.

Multiple Myeloma Progression Influenced by Immune Microenvironment Expression

Researchers in NPJ Genomic Medicine compare RNA sequencing profiles of 102,207 individual cells in bone marrow samples from 18 individuals with rapid or non-progressing multiple myeloma.

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.